134 related articles for article (PubMed ID: 14751145)
21. Clinicopathological analysis of mixed endometrial carcinomas: clinical relevance of different neoplastic components.
Rossi ED; Bizzarro T; Monterossi G; Inzani F; Fanfani F; Scambia G; Zannoni GF
Hum Pathol; 2017 Apr; 62():99-107. PubMed ID: 28041971
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of special AT-rich sequence-binding protein 1 in endometrial cancer: a clinicopathologic study.
Zhang Y; Wang L; Liu Y; Meng F; Wang S; Shang P; Gao Y; Chen X
Int J Gynecol Cancer; 2015 Jan; 25(1):4-11. PubMed ID: 25347096
[TBL] [Abstract][Full Text] [Related]
23. GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma.
Idrees MT; Schlosshauer P; Li G; Burstein DE
Histopathology; 2006 Jul; 49(1):75-81. PubMed ID: 16842248
[TBL] [Abstract][Full Text] [Related]
24. SLUG expression is an indicator of tumour recurrence in high-grade endometrial carcinomas.
Kihara A; Wakana K; Kubota T; Kitagawa M
Histopathology; 2016 Sep; 69(3):374-82. PubMed ID: 27003026
[TBL] [Abstract][Full Text] [Related]
25. May cathepsin D immunoreactivity be used as a prognostic factor in endometrial carcinomas? A comparative immunohistochemical study.
Saygili U; Koyuncuoglu M; Altunyurt S; Guclu S; Uslu T; Erten O
Gynecol Oncol; 2001 Oct; 83(1):20-4. PubMed ID: 11585409
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical study of fatty acid synthase in ovarian neoplasms.
Alò PL; Visca P; Framarino ML; Botti C; Monaco S; Sebastiani V; Serpieri DE; Di Tondo U
Oncol Rep; 2000; 7(6):1383-8. PubMed ID: 11032949
[TBL] [Abstract][Full Text] [Related]
27. Clusterin immunoexpression is associated with early stage endometrial carcinomas.
Al-Maghrabi JA; Butt NS; Anfinan N; Sait K; Sait H; Bajouh O; Khabaz MN
Acta Histochem; 2016 May; 118(4):430-4. PubMed ID: 27079858
[TBL] [Abstract][Full Text] [Related]
28. Uterine carcinosarcoma and high-risk endometrial carcinomas: a clinicopathological comparison.
Zhang C; Hu W; Jia N; Li Q; Hua K; Tao X; Wang L; Feng W
Int J Gynecol Cancer; 2015 May; 25(4):629-36. PubMed ID: 25633654
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological significance of PSF3 expression in uterine endometrial carcinomas.
Park JK; Otsuka N; Tomaru U; Suzuki H; Azuma M; Okamoto K; Yamashiro K; Kasahara M
Hum Pathol; 2018 Oct; 80():104-112. PubMed ID: 29936059
[TBL] [Abstract][Full Text] [Related]
30. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathologic and survival analysis of synchronous primary endometrial and ovarian cancer].
Wang Y; Yu M; Yang JX; Cao DY; Zhang Y; Shen K; You Y
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):816-822. PubMed ID: 30585019
[No Abstract] [Full Text] [Related]
32. Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma.
Coppola D; Fu L; Nicosia SV; Kounelis S; Jones M
Hum Pathol; 1998 May; 29(5):455-62. PubMed ID: 9596268
[TBL] [Abstract][Full Text] [Related]
33. Small Foci of Serous Component as a Predictor of Recurrence and Prognosis for Stage IA Endometrial Carcinomas.
Miyamoto M; Takano M; Tsuda H; Soyama H; Aoyama T; Ishibashi H; Kato K; Iwahashi H; Matuura H; Yoshikawa T; Suzuki A; Hirata J; Furuya K
Oncology; 2017; 93(1):29-35. PubMed ID: 28259868
[TBL] [Abstract][Full Text] [Related]
34. Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma.
Mhawech-Fauceglia P; Wang D; Samrao D; Liu S; DuPont NC; Pejovic T
Gynecol Oncol; 2013 Jul; 130(1):174-80. PubMed ID: 23578537
[TBL] [Abstract][Full Text] [Related]
35. [Predictors of recurrence and prognosis in patients with stage I and II endometrial carcinoma].
Li M; Wang Z; Zhao L; Li X; Wang J; Zhang C; Wei L
Zhonghua Fu Chan Ke Za Zhi; 2014 Jun; 49(6):455-9. PubMed ID: 25169640
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia.
Kalir T; Wang BY; Goldfischer M; Haber RS; Reder I; Demopoulos R; Cohen CJ; Burstein DE
Cancer; 2002 Feb; 94(4):1078-82. PubMed ID: 11920478
[TBL] [Abstract][Full Text] [Related]
37. Fatty acid synthase expression in Paget's disease of the vulva.
Alo PL; Galati GM; Sebastiani V; Ricci F; Visca P; Mariani L; Romagnoli F; Lombardi G; Tondo UD
Int J Gynecol Pathol; 2005 Oct; 24(4):404-8. PubMed ID: 16175090
[TBL] [Abstract][Full Text] [Related]
38. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients.
Alo' PL; Visca P; Marci A; Mangoni A; Botti C; Di Tondo U
Cancer; 1996 Feb; 77(3):474-82. PubMed ID: 8630954
[TBL] [Abstract][Full Text] [Related]
39. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
40. Decreased hyaluronidase 1 expression is associated with early disease recurrence in human endometrial cancer.
Nykopp TK; Pasonen-Seppänen S; Tammi MI; Tammi RH; Kosma VM; Anttila M; Sironen R
Gynecol Oncol; 2015 Apr; 137(1):152-9. PubMed ID: 25584766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
